A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 951-955

  Takei, Yuji ^a   Suzuki, Mitsuaki ^a   Ohwada, Michitaka ^a   Saga, Yasushi ^a   Kohno, Takahiro ^a   Machida, Shizuo ^a   Sato, Ikuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Combination chemotherapy; Feasibility study; Japanese women; Ovarian cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEASIBILITY STUDY; FEMALE; HUMAN; MIDDLE AGED; NEOPLASM; OVARY TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 1542577513     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.951     Document Type: Article

References (22)

1. Sugawa T, Umesaki N, Yajima A, Satoh S, Terashima Y, Ohiai K, Tomoda Y, Kanoh T, Noda K, Yakushiji M and Nishimura H: Effect of chemothrapy on the prognosis of ovarian cancer. Acta Obstet Gynaecol Jpn 44: 1135-1141, 1992.
2. Yakushiji M, Sugiyama T and Ushijima K: Promising new drugs for gynecological cancer. Gan To Kagaku Ryoho 24: 1932-1937, 1997. (Pubitemid 27491769)
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burneil M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evalustion of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989. (Pubitemid 19272848)
4. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO, Geneva, pp23-24, 1979.
5. Blessing JA: Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer. In: Chemotherapy of Gynecologic Cancer (2nd edition). Deppe G (ed). Wiley-Liss, New York, pp63-97, 1990.
6. Japan Society of Clinical Oncology Committee on Criteria for Efficacy of Cancer Therapy: Adverse drug reaction criteria of the japan society of clinical oncology. Int J Clin Oncol 2: 177-179, 1997.
7. 2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin Oncol 24: S15-36-S15-39, 1997.
8. Neijt JP, Engelholm SA, Tuxen MK, Sørensen PG, Hansen M, Sessa C, De Swart C, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarina cancer. J Clin Oncol 18: 3084-3092, 2000.
9. Mcguire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996. (Pubitemid 26012496)
10. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergoup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000. (Pubitemid 30365530)
11. Conte PF, Bruzzone M, Camino F, Chiara S, Donadio M, Facchini V, Fioretti P, Foglia G, Gadducci A, Gallo L, Giaccone G, Guercio E, Iskra L, Janssen N, Maresi MP, Parodi G, Ragni N, Rosso R, Rubagotti A, Rugiati S, Strace A, Venfurini S and Pescetto G: Carboplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithlial ovarian cancer. J Clin Oncol 9: 658-663, 1991.
12. De Oliveira CF, Lacave AJ, Villani C, Wolff JP, Dire F, Namer M, Maskens A, George M, Dalesio O, Rotmensz N and Vermorken JB: Randomized comparison of cyclophosphamide, doxorubicin and ciaplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). Eur J Gynaecol Oncol 11: 323-330, 1990.
13. Marth C, Trope C, Vergote IB and Kristensen GB: Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. Eur J Cancer 34: 1175-1180, 1998. (Pubitemid 28342105)
14. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B and Pater J; Cisplatin-cyclophosphamide versus carboplatin- cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 10: 718-726, 1992.
15. Du Bois A, Luck HJ, Bauknecht T, Mobus V, Bochtler H, Diergarten K and Meerpohl HG: Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithlial ovarian cancer. Ann Oncol 8: 355-361, 1997. (Pubitemid 27230976)
16. Bolis G, Scarfone G, Zanaboni F, Villa A, Presti M, Melpignano M, Ferraris C, Tateo S, Guarnerio P, Gentile A and Parazzini F: A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Eur J Cancer 33: 592-595, 1997. (Pubitemid 27223743)
17. Huizing MT, van Warmerdam LJC, Rosing H, Schaefers MCW, Lai A, Helmerhorst TJM, Veenhof CHN, Birkhofer MJ, Rodenhuis S, Beijnen JH and ten Bokkel Huinink WW: Phase I and Pharmacologic study of combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15: 1953-1964, 1997. (Pubitemid 27209526)
18. Skarlos D, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C and Fountzilas G: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology group study. Semin Oncol 24: S15-57-S15-61, 1997.
19. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584-2589, 2000.
20. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T and Nagata I: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331, 2000.
21. Shimizu Y, Umezawa S and Hasumi K: A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 27: 650-656, 1998. (Pubitemid 29037230)
22. Kosmidis P, Mylonakis N, Dimopoulos A, Pavlidis N, Fountzilas G, Samantas E, Dimitriadis K, Kalophonos C, Tsavdaridis D and Skarlos D: Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Semin Oncol 27: 3-8, 2000. (Pubitemid 30108677)